Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Jean A. Klastersky
Professor Klastersky was Head of the Department of Medicine at the Institut Jules Bordet in Brussels, Belgium, and Professor of Medicine, Medical Oncology and Physical Diagnosis at the Université Libre de Bruxelles, Belgium, from 1977. He retired from these positions in 2005. Currently, he is the coordinator of the “Programme des Soins Oncologiques” for the Public Hospitals in Brussels and consultant in medical oncology at the Institut Jules Bordet, Belgium.
Professor Klastersky was an intern and resident at the University Hospitals of the Université Libre de Bruxelles between 1962 and 1965, where he gained his MD (Docteur en Médecine, Chirurgie et Accouchements). From 1967 to 1968, he was Chief-Resident at Boston City Hospital, USA, and then a Research Fellow and Assistant in Medicine at Thorndike Memorial Laboratory Harvard Medical School, USA. He became Chief of the Section of Infectious Diseases at the Institut Jules Bordet in 1970, before taking up the position of Head of the Department of Medicine in 1977.
Professor Klastersky was a founder member of the European Lung Cancer Working Party and was President from 1978 until 2003. He was President (and founder member) of the International EORTC Antimicrobial Therapy Project Group between 1979 and 1987 and the Group's Secretary General from 1987 to 2000. He was President (and founder member) of the Multinational Association for Supportive Care in Cancer (MASCC) from 1990 to 2000.
He has been Visiting Professor of Medical Oncology at the Charles University in Prague, Czech Republic, since 1994.
Professor Klastersky is a member of the American Society of Clinical Oncology, the American Association of Cancer Research, the European Society of Medical Oncology, the American Society of Microbiology, the Infectious Diseases Society of America, the International Association for the Study of Lung Cancer, the “Royale Académie de Médecine” of Belgium and various other international and national medical and/or oncological societies.
Professor Klastersky is the author of over 400 original articles, nearly 400 review articles and 17 scientific books.
He is the Editor of Current Opinion in Oncology.
Professor Jean-Yves Blay, M.D., Ph.D, is the Director of the Centre Léon Bérard, the comprehensive cancer center of Lyon since December 2014. He is also a Professor of Medical Oncology, a researcher and a medical oncologist professor at the University Claude Bernard Lyon1, France, and a corresponding member of the French Academy of Medicine.
Since October 2019, he is the President of the French Federation of Comprehensive Cancer Centers, Unicancer.
Professor Blay has published over 600 peer-reviewed articles. He was President of the European Organization for Research and Treatment of Cancer (EORTC) from 2009 to 2012. He has also received numerous awards such as the Hamilton Fairley Award in 2012 from the ESMO and the Henry and Mary-Jane Mitjavile prize in 2013 from the National Academy of Medicine.
Currently President of the French Sarcoma Group GETO, he is the network leader of the NETSARC network of reference centers for sarcoma treatment certified by the French National Cancer Institute, the former PI of Conticanet (a FP6 network of excellence), and the current PI of the FP7 project EuroSARC).
He is the Director of the Integrated Centre for innovation on Cancer Research of Lyon (LYRIC). He is the Network Director of the European Reference Network EURACAN (euracan.org).
His research interests focus on clinical and basic research in sarcomas, targeted treatment of cancer, the biology of breast carcinoma and relation between tumor immunologic microenvironment and malignant cells with the goal of clinical applications in the fields of diagnosis, prognosis and treatment.
Dr Alain Hendlisz is a Board-certified gastro-enterologist. He gained his MD (Docteur en Médecine, Chirurgie et Accouchements) at the Université Libre de Bruxelles, Belgium in 1988 and has been a specialist in gastroenterology since 1993. He earned his PhD in Medical Sciences at the ULB in 2015. He is currently Head of the Gastroenterology Unit at the Institut Jules Bordet, Anti-Cancer Center of the Université Libre de Bruxelles
He is a founding member and is currently serving as vice-chairman on the Board of the BGDO (Belgian Group for Digestive Oncology). He is a member of the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), the Société Royale Belge de Gastro-entérologie (SRBG) and European Organization for Research and Treatment of Cancer (EORTC).
He is involved as principal investigator or co-investigator in numerous national and international clinical studies.
Dr Francesco Sclafani is a Consultant Medical Oncologist working as Chef de Clinique in the Gastrointestinal Unit of the Institut Jules Bordet in Brussels, Belguim. He is specialised in the treatment of gastrointestinal cancers. He graduated from the University of Palermo, Italy, in 2003 and completed his specialist Medical Oncology training at the University of Milan, Italy, in 2009. He worked at the St Vincent's University Hospital in Dublin (2010–2012) and in the Gastrointestinal Unit at The Royal Marsden NHS Foundation Trust in London (2012–2018).
He was awarded an MD (Res) degree and the Chairman's prize for Outstanding Graduating MD (Res) Student at the University of London – Institute of Cancer Research, UK, in 2018. He is Lecturer (Maître de Conférence) at the Université Libre de Bruxelles, Belgium. He is member of the ESMO Gastrointestinal Faculty, co-Chair of the EORTC Colon Cancer Task Force, and Co-Chair of the ECCO Essential Requirements for Quality Cancer Care (ERQCC) initiative for pancreatic cancer.
He is an active member of international cooperative groups such as the EORTC Gastrointestinal Tumour Study Group and the International Rare Cancer Initiative Anal Cancer Working Subgroup. He is investigator of a number of phase I-IV clinical trials in gastrointestinal cancers, and he has published over 90 peer-reviewed articles and book chapters.